Evolve Executive Life Coaching founder Shayla King announced enrollment for The Performance + Happiness Lab, a coaching program designed to help senior leaders advance their careers while maintaining work-life balance. The program addresses challenges faced by high-performing executives who achieve results but experience burnout, helping them strengthen positioning, build influence, and pursue sustainable career growth.
McKesson Corporation (MCK)
Common Stock · Currency in USD · XNYS
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Company Info
SIC5122
Composite FIGIBBG000DYGNW7
CIK0000927653
IPOAug 3, 1987
Sectorwholesale-drugs, proprietaries & druggists' sundries
Highlights
Market Cap$108.31B
EPS$38.52
P/E Ratio21.66
Revenue$418.62B
Gross Profit$14.74B
Net Income$5.00B
Employees51,000
WSO122,487,456
Phone972-446-4800
Websitehttps://www.mckesson.com
Related Tickers
AMN
AMN Healthcare Services
$18.20 0.00%
HSIC
Henry Schein Inc
$73.94 0.00%
HOLX
Hologic Inc
$75.65 0.00%
BIO
Bio-Rad Laboratories, Inc.Class A
$279.99 0.00%
HQY
HealthEquity, Inc
$84.67 0.00%
ITGR
Integer Holdings Corporation
$86.85 0.00%
WST
West Pharmaceutical Services, Inc.
$253.88 0.00%
MMSI
Merit Medical Systems Inc
$67.70 0.00%
HUM
Humana Inc.
$179.02 0.00%
CRL
Charles River Laboratories International, Inc.
$173.89 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in McKesson Corporation, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
McKesson Corporation (MCK) has returned 8.10% so far this year and 33.34% over the past 12 months. Looking at the last ten years, MCK has achieved an annualized return of 18.85%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
MCK
1M-6.73%
6M20.00%
YTD8.10%
1Y33.34%
5Y36.02%
10Y18.85%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of McKesson Corporation (MCK) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.61% | 18.09% | -12.59% | 2.46% | ||||||||
| 2025 | 3.83% | 7.79% | 5.55% | 5.41% | 1.76% | 2.03% | -5.49% | -1.58% | 12.40% | 5.33% | 8.31% | -6.33% |
| 2024 | 8.04% | 4.78% | 2.55% | 0.18% | 7.01% | 3.23% | 5.22% | -9.65% | -12.79% | 1.82% | 23.85% | -8.88% |
| 2023 | 1.59% | -6.64% | 2.22% | 1.58% | 7.03% | 8.92% | -4.81% | 2.44% | 5.22% | 5.03% | 3.75% | -2.01% |
| 2022 | 3.71% | 6.98% | 11.43% | 1.06% | 5.43% | -1.49% | 4.88% | 7.93% | -7.37% | 13.82% | -1.63% | -1.93% |
| 2021 | 0.11% | -3.92% | 13.96% | -3.73% | 1.52% | 1.12% | 6.21% | 0.15% | -2.05% | 4.02% | 3.92% | 13.19% |
| 2020 | 2.52% | -2.22% | -4.46% | 8.27% | 14.04% | -3.10% | -2.12% | -1.43% | -3.40% | -1.31% | 19.67% | -4.99% |
| 2019 | 16.74% | 2.91% | -8.27% | 1.06% | 2.07% | 9.90% | 2.93% | -4.46% | -0.68% | -3.23% | 7.92% | -4.22% |
| 2018 | 7.63% | -9.22% | -5.78% | 11.37% | -8.78% | -6.68% | -5.73% | 2.44% | 3.38% | -6.17% | -0.78% | -10.21% |
| 2017 | -0.89% | 7.47% | -2.01% | -6.80% | 17.91% | 1.16% | -2.07% | -8.57% | 2.76% | -10.36% | 6.46% | 6.06% |
| 2016 | 7.06% | 9.14% | 2.71% | 4.03% | -5.42% | -9.73% | -23.49% | 13.08% | -2.08% |
Performance Indicators
The charts below present risk-adjusted performance metrics for McKesson Corporation (MCK) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MCK compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current McKesson Corporation volatility is 1.56%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 75.14B | 67.44B | 62.32B | 63.30B | 65.02B | 61.25B | 59.67B | 60.38B | 60.97B | 56.56B | 53.87B | 51.76B | 34.79B | 33.09B | 30.89B | 28.19B |
| Temporary Equity (USD) | - | - | - | - | 1.27B | 1.40B | 1.39B | 1.46B | 1.33B | 1.41B | 1.39B | - | - | - | - | - |
| Equity Attributable To Parent (USD) | -2.07B | -1.97B | -1.86B | -2.27B | -21.00M | 5.09B | 8.09B | 9.80B | 11.10B | 8.92B | 8.00B | 8.52B | 7.07B | 6.83B | 7.22B | 7.53B |
| Equity Attributable To Noncontrolling Interest (USD) | 380.00M | 372.00M | 367.00M | 480.00M | 196.00M | 217.00M | 193.00M | 253.00M | 178.00M | 84.00M | 84.00M | 1.80B | - | - | - | - |
| Equity (USD) | -1.69B | -1.60B | -1.49B | -1.79B | 175.00M | 5.31B | 8.29B | 10.06B | 11.27B | 9.01B | 8.09B | 10.32B | 7.07B | 6.83B | 7.22B | 7.53B |
| Redeemable Noncontrolling Interest, Common (USD) | - | - | - | - | 1.27B | 1.40B | 1.39B | 1.46B | 1.33B | 1.41B | 1.39B | - | - | - | - | - |
| Redeemable Noncontrolling Interest (USD) | - | - | - | - | 1.27B | 1.40B | 1.39B | 1.46B | 1.33B | 1.41B | 1.39B | - | - | - | - | - |
| Commitments and Contingencies (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Non-current Liabilities (USD) | 9.58B | 11.06B | 10.26B | 10.75B | 13.59B | 5.93B | 6.16B | 5.76B | 5.72B | 4.34B | 2.58B | 1.57B | 1.49B | 996.00M | 936.00M | - |
| Long-term Debt (USD) | 5.65B | 5.63B | 5.59B | 5.88B | 7.15B | 7.39B | 7.60B | 7.88B | 8.36B | 8.15B | 9.71B | 10.37B | 4.87B | 3.58B | 4.00B | - |
| Noncurrent Liabilities (USD) | 15.23B | 16.69B | 15.85B | 16.62B | 20.74B | 13.31B | 13.76B | 13.64B | 14.08B | 12.48B | 12.29B | 11.94B | 6.36B | 4.58B | 4.94B | 3.65B |
| Other Current Liabilities (USD) | 6.27B | 5.26B | 5.47B | 10.38B | 5.13B | 5.43B | 3.77B | 4.51B | 4.59B | 6.49B | 8.33B | 8.07B | 5.25B | 5.57B | 4.64B | 3.76B |
| Accounts Payable (USD) | 55.33B | 47.10B | 42.49B | 38.09B | 38.98B | 37.20B | 33.85B | 32.18B | 31.02B | 28.59B | 25.17B | 21.43B | 16.11B | 16.11B | 14.09B | 13.26B |
| Current Liabilities (USD) | 61.60B | 52.36B | 47.96B | 48.47B | 44.10B | 42.62B | 37.63B | 36.69B | 35.61B | 35.07B | 33.50B | 29.50B | 21.36B | 21.69B | 18.73B | 17.01B |
| Liabilities (USD) | 76.83B | 69.04B | 63.81B | 65.09B | 64.84B | 55.94B | 51.39B | 50.32B | 49.70B | 47.56B | 45.79B | 41.44B | 27.72B | 26.26B | 23.67B | 20.66B |
| Other Non-current Assets (USD) | 17.24B | 17.16B | 15.85B | 14.98B | 17.05B | 16.66B | 18.66B | 20.78B | 21.73B | 15.85B | 15.16B | 16.96B | 10.30B | 6.70B | 6.08B | 5.28B |
| Intangible Assets (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75B | 1.46B | 551.00M |
| Fixed Assets (USD) | 2.50B | 2.32B | 2.18B | 2.09B | 2.58B | 2.37B | 2.55B | 2.46B | 2.29B | 2.28B | 2.05B | 2.22B | 1.32B | 1.04B | 991.00M | 851.00M |
| Noncurrent Assets (USD) | 19.74B | 19.47B | 18.03B | 17.07B | 19.63B | 19.03B | 21.21B | 23.25B | 24.02B | 18.13B | 17.20B | 19.19B | 11.62B | 9.49B | 8.53B | 6.69B |
| Other Current Assets (USD) | 6.75B | 5.21B | 5.19B | 8.95B | 6.96B | 5.54B | 3.51B | 3.12B | 3.46B | 5.12B | 6.46B | 5.07B | 2.86B | 3.55B | 3.95B | 3.99B |
| Inventory (USD) | 23.00B | 21.14B | 19.69B | 18.70B | 19.25B | 16.73B | 16.71B | 16.31B | 15.28B | 15.34B | 14.30B | 13.31B | 10.34B | 10.07B | 9.23B | 9.44B |
| Accounts Receivable (USD) | 25.64B | 21.62B | 19.41B | 18.58B | 19.18B | 19.95B | 18.25B | 17.71B | 18.22B | 17.98B | 15.91B | 14.19B | 9.98B | 9.98B | 9.19B | 8.08B |
| Current Assets (USD) | 55.40B | 47.97B | 44.29B | 46.23B | 45.38B | 42.22B | 38.47B | 37.14B | 36.95B | 38.44B | 36.67B | 32.57B | 23.17B | 23.60B | 22.36B | 21.50B |
| Assets (USD) | 75.14B | 67.44B | 62.32B | 63.30B | 65.02B | 61.25B | 59.67B | 60.38B | 60.97B | 56.56B | 53.87B | 51.76B | 34.79B | 33.09B | 30.89B | 28.19B |
News and Insights
The global cardiology EHR market is valued at USD 3.52 billion in 2026 and is expected to reach USD 5.44 billion by 2035, growing at a 4.95% CAGR. North America leads the market while Asia Pacific shows the fastest growth. Web/cloud-based EHR systems dominate the product segment, with ambulatory surgery centers expected to grow fastest by end-use category.
Software's Freefall Continues, Bitcoin Dips To 16-Month Lows: What's Moving Markets Thursday?positive
Software stocks plunged for an eighth consecutive session on Thursday, marking their longest losing streak since May 2021, as investors worry AI could undermine SaaS demand. Bitcoin fell 9% to $66,000, hitting 16-month lows, while commodities suffered broad declines. Major indices traded modestly lower, with notable losers including Estée Lauder (down 23% on tariff concerns), Palantir (down 4.4%), and Qualcomm (down 7% on weak guidance). Winners included McKesson (up 15.8%), Regal Rexnord (up 13%), and Uber (up 3%).
Medline Industries, the largest IPO of 2025, is positioned as an attractive investment opportunity. The Chicago-based medical supply company has demonstrated strong historical growth with 18% average annual sales growth since 1966 and 50 consecutive years of net sales growth. With a $375 billion total addressable market and solid free cash flow projections, analysts expect continued momentum, though the stock trades at a lofty P/E multiple of 28.
AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing accessibility for hospitals and health systems nationwide.
Zuckerman Investment Group increased its Henry Schein stake by 72,040 shares in Q3, bringing its position to 281,339 shares valued at $18.67 million. The purchase reflects confidence in Henry Schein's improving fundamentals, including 5% revenue growth to $3.3 billion, 13% non-GAAP EPS growth to $1.38, and a new $200 million efficiency plan. The company also repurchased $229 million in stock during the quarter.
The global automated pharmacy compounding systems market is projected to grow from USD 2.95 billion in 2025 to USD 5.27 billion by 2035, driven by the need to reduce medication errors, demand for personalized medicine, and stringent regulatory standards.
Iterum Therapeutics reports expanding market access for ORLYNVAH™, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.
The global healthcare supply chain management market is projected to grow from $3.60 billion in 2025 to $9.20 billion by 2034, with a CAGR of 11.05%. North America leads the market, driven by technological advancements, AI integration, and demand for efficient healthcare logistics.
The Practice Management Systems market is expected to grow to $36.33 billion by 2031, with a 9.3% CAGR, driven by digital healthcare solutions, operational efficiency needs, and increasing telemedicine adoption.